# COVID-19 Ozanimod Intervention Study

> **NCT04405102** · PHASE2 · TERMINATED · sponsor: **Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec** · enrollment: 43 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Ozanimod
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04405102
- **Lead sponsor:** Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-16
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-05-12
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405102, "COVID-19 Ozanimod Intervention Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04405102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*